U.S. Markets closed

A Look at Novo Nordisk’s Human Insulin and Obesity Business

Daniel Collins
A Look at Novo Nordisk’s Human Insulin and Obesity Business

In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.